Illumina to Record $1.47 Goodwill Impairment Charge in Q2 After Grail Spin-Off
Barclays Maintains Illumina(ILMN.US) With Sell Rating, Maintains Target Price $100
Express News | Illumina Inc - Charge as a Result of Impairment Test Performed by Co for Goodwill and Non-Amortizing in-Process Research and Development
Express News | Illumina Inc - Estimates That It Will Recognize an Impairment Charge for Grail Ipr&D Intangible Asset in Q2 of 2024 Equal to $420 Mln
Express News | Illumina Inc - Does Not Expect Any Material Future Cash Expenditures Related to Impairments
Express News | Illumina Inc - Estimates That It Will Recognize a Goodwill Impairment Charge in the Second Quarter of 2024 Equal to $1,466 Million
Baird Maintains Illumina(ILMN.US) With Hold Rating, Cuts Target Price to $119
Cancer detection product supplier Grail (GRAL.US) will debut on Nasdaq tonight, having split from Illumina (ILMN.US).
Grail, a cancer detection product supplier split off from life science company Illumina, went public on Nasdaq on Tuesday.
Grail to Begin Trading as Illumina Completes Spinoff
Cancer blood test developer Grail launches trading on Nasdaq, valuing it at about $7 billion
Illumina Completes Grail Spin-Off Into Publicly Traded Entity, Holds Minority Stake
Illumina Finishes Spinning Off Cancer-Test Maker Grail -- WSJ
GRAIL Will Be Listed And Commence Regular-Way Trading On The Nasdaq Under The Symbol "GRAL" As Of June 25, 2024.
Express News | Illumina Inc - Grail Spin-off Complete; Grail to Begin Regular Way Trading as "Gral" on June 25
Express News | Illumina Completes the Divestiture of Grail
GRAIL to Begin Trading on the Nasdaq Stock Exchange
Illumina Completes the Divestiture of GRAIL
Long-term Beneficiaries of AI, According to Goldman Sachs
Guggenheim Initiates Illumina(ILMN.US) With Buy Rating, Announces Target Price $138
Express News | Illumina Inc : Guggenheim Cuts Target Price to $138 From $159